Lineage Cell Therapeutics and Cancer Research UK Report Topline Phase 1 Study Results With VAC2 for the Treatment of Advanced Non-small Cell Lung Cancer

advantage of their expertise in cancer immunotherapy. The Phase 1 study on VAC2, a potential treatment for advanced non-small cell lung cancer (NSCLC), has yielded promising results. In this study, five out of eight patients experienced immune-related stable disease as their best response. This is a significant finding, as it indicates that the treatment has the potential to stabilize the progre..